Search results for "CyclinE"

showing 10 items of 194 documents

The lipid lowering drug lovastatin protects against doxorubicin-induced hepatotoxicity.

2012

Liver is the main detoxifying organ and therefore the target of high concentrations of genotoxic compounds, such as environmental carcinogens and anticancer drugs. Here, we investigated the usefulness of lovastatin, which is nowadays widely used for lipid lowering purpose, as a hepatoprotective drug following the administration of the anthracycline derivative doxorubicin in vivo. To this end, BALB/c mice were exposed to either a single high dose or three consecutive low doses of doxorubicin. Acute and subacute hepatotoxicities were analyzed with or without lovastatin co-treatment. Lovastatin protected the liver against doxorubicin-induced acute pro-inflammatory and pro-fibrotic stress respo…

Liver CirrhosisStatinAnthracyclinemedicine.drug_classBiologyPharmacologyToxicologymedicine.disease_causeMiceFibrosispolycyclic compoundsmedicineAnimalsDoxorubicinLovastatinRNA MessengerEpirubicinPharmacologyInflammationMice Inbred BALB CAntibiotics AntineoplasticDose-Response Relationship DrugConnective Tissue Growth Factormedicine.diseaseOxidative StressHepatoprotectionGene Expression RegulationDoxorubicinHMG-CoA reductasebiology.proteinlipids (amino acids peptides and proteins)LovastatinChemical and Drug Induced Liver InjuryHydroxymethylglutaryl-CoA Reductase InhibitorsOxidative stressmedicine.drugDNA DamageToxicology and applied pharmacology
researchProduct

Direct conversion of human fibroblast to hepatocytes using a single inducible polycistronic vector

2019

Abstract Background Human fibroblasts can be reprogrammed into induced hepatocyte-like cells through the expression of a set of transcription factors. Although the generation of induced hepatocyte-like cells by HNF4A, HNF1A, and FOXA3 expression has proven to be a robust experimental strategy, using multiple lentivirus results in a highly variable heterogeneous population. Methods We designed and implemented a novel approach based on the delivery of reprogramming factors and green fluorescent protein in a single doxycycline-inducible lentiviral vector using 2A self-cleaving peptides. Results Fibroblasts infected with the lentiviral vector can be amplified in basic fibroblast culture media i…

Male0301 basic medicineInducibleGenetic VectorsGreen Fluorescent ProteinsMedicine (miscellaneous)Biochemistry Genetics and Molecular Biology (miscellaneous)Cell LineViral vectorGreen fluorescent proteinlcsh:BiochemistryMice03 medical and health sciences0302 clinical medicinePolycistronic vectorsmedicineAnimalsHumanslcsh:QD415-436TransgenesFibroblastGeneTranscription factorlcsh:R5-920ChemistryResearchReprogrammingDermisCell BiologyFibroblastsCellular ReprogrammingCell biologyInduced hepatocyte-like cellsiHEPPhenotype030104 developmental biologymedicine.anatomical_structureGenes030220 oncology & carcinogenesisDoxycyclineHepatocytesMolecular MedicineFOXA3Stem celllcsh:Medicine (General)ReprogrammingStem Cell Research & Therapy
researchProduct

Both cholestatic and steatotic drugs trigger extensive alterations in the mRNA level of biliary transporters in rat hepatocytes: Application to devel…

2016

Disruption of the vectorial bile acid transport in the liver is a key feature of cholestatic drugs, although many causal and mechanistic aspects are still unknown. The aim of the present study was to explore if cholestatic drugs can repress or induce the expression of hepatic transporters. To this end, sandwich-cultured rat hepatocytes were treated with cholestatic and non-cholestatic (steatotic, non-hepatotoxic, etc.) drugs and the mRNA expression of 10 uptake and efflux biliary transporters was measured. Results evidenced that all cholestatic drugs cause extensive alterations in the mRNA expression of most biliary transporters. Surprisingly, nearly all steatotic drugs also affected the ex…

Male0301 basic medicinePathologymedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsDrug Evaluation PreclinicalOrganic Anion Transporters Sodium-IndependentPharmacologyBiologyToxicology030226 pharmacology & pharmacyRats Sprague-Dawley03 medical and health sciences0302 clinical medicineCholestasisPredictive Value of TestsIn vivomedicineAnimalsBileRNA MessengerCells CulturedCholestasisMultidrug resistance-associated protein 2Fatty liverTransporterGeneral Medicinemedicine.diseaseRatsFatty Liver030104 developmental biologyTetracyclinesHepatocytesBiomarker (medicine)EffluxSteatosisCarrier ProteinsBiomarkersToxicology Letters
researchProduct

Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemother…

2011

Background Fms-like tyrosine kinase-3 (FLT3) gene mutations are frequent in acute promyelocytic leukemia but their prognostic value is not well established. Design and Methods We evaluated FLT3-internal tandem duplication and FLT3-D835 mutations in patients treated with all-trans retinoic acid and anthracycline-based chemotherapy enrolled in two subsequent trials of the Programa de Estudio y Tratamiento de las Hemopatias Malignas (PETHEMA) and Hemato-Oncologie voor Volwassenen Nederland (HOVON) groups between 1996 and 2005. Results FLT3-internal tandem duplication and FLT3-D835 mutation status was available for 306 (41%) and 213 (29%) patients, respectively. Sixty-eight (22%) and 20 (9%) pa…

MaleAIDA PROTOCOLGene mutationmedicine.disease_causeGastroenterologyLeukemia Promyelocytic AcuteRESIDUAL DISEASEhemic and lymphatic diseasesMOLECULAR SUBTYPESChildanthracyclinesMutationRemission InductionFLT3 mutationshemic and immune systemsHematologyMiddle AgedPrognosisall-trans retinoic acidLeukemiaTreatment Outcomeembryonic structuresFemaleTandem exon duplicationmedicine.drugAcute promyelocytic leukemiaAdultmedicine.medical_specialtyAdolescentAntineoplastic AgentsTretinoinACUTE MYELOID-LEUKEMIABiologyYoung AdultQUALITY-CONTROLTretinoinPOOR-PROGNOSISInternal medicinemedicineCoagulopathyHumansAgedprognostic factorsOriginal Articlesacute promyelocytic leukemiamedicine.diseaseSurvival AnalysisINTERNAL TANDEM DUPLICATIONRISK-ADAPTED TREATMENTPML/RAR-ALPHAfms-Like Tyrosine Kinase 3Fms-Like Tyrosine Kinase 3ImmunologyPETHEMA GROUPMutation
researchProduct

Epidemiology and clonality of carbapenem-resistant Acinetobacter baumannii from an intensive care unit in Palermo, Italy

2012

Abstract Background Multidrug-resistant Acinetobacter baumannii, initially considered as having a poor clinical relevance, is frequently isolated from infection cases in intensive care units. We describe the epidemiology of carbapenem resistant A. baumannii (CRAB) in a general ICU in Palermo, Italy, from October 2010 to March 2011. Findings 58 of 61 isolates exhibited MICs for meropenem or imipenem ≥16 mg/L. Forty-nine carried blaOXA-23 and two blaOXA-58 genes. Five subtype clusters were detected by rep-PCR. Clusters D and E included 10 isolates that tested negative for the carbapenem resistance genes. MLST attributed all isolates, but two, with sequence type (ST)2, whereas the two remainin…

MaleAcinetobacter baumanniiImipenemSettore MED/07 - Microbiologia E Microbiologia ClinicaTime Factorslcsh:MedicineTigecyclinePolymerase Chain Reactionintensive care unitlaw.inventionlawDrug Resistance Multiple BacterialEpidemiologypolycyclic compoundsMedicinelcsh:QH301-705.5Medicine(all)Aged 80 and overbiologyGeneral MedicineMiddle AgedIntensive care unitAcinetobacter baumanniiIntensive Care UnitsItalyFemaleAcinetobacter baumannii; intensive care unitAcinetobacter Infectionsmedicine.drugAdultmedicine.medical_specialtyAdolescentShort ReportMicrobial Sensitivity TestsMeropenemGeneral Biochemistry Genetics and Molecular BiologyYoung AdultIntensive careHumansIntensive care medicinelcsh:Science (General)AgedDemographyBiochemistry Genetics and Molecular Biology(all)business.industrylcsh:Rbiochemical phenomena metabolism and nutritionbacterial infections and mycosesbiology.organism_classificationClone CellsCarbapenemslcsh:Biology (General)bacteriabusinessCarbapenem resistant Acinetobacter baumanniilcsh:Q1-390BMC Research Notes
researchProduct

Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy

2018

Treatment outcome in older patients with acute promyelocytic leukemia (APL) is lower compared with younger patients, mainly because of a higher induction death rate and postremission non-relapse mortality (NRM). This prompted us to design a risk-and age-adapted protocol (Programa Espanol de Tratamientos en Hematologia (PETHEMA)/HOVON LPA2005), with dose reduction of consolidation chemotherapy. Patients aged >= 60 years reported to the PETHEMA registry and were treated with all-trans retinoic acid (ATRA) plus anthracycline-based regimens according to three consecutive PETHEMA trials that were included. We compared the long-term outcomes of the LPA2005 trial with the preceding PETHEMA tria…

MaleAcute promyelocytic leukemiaCancer Researchmedicine.medical_specialtyAnthracyclinemedicine.medical_treatmentTretinoinACUTE MYELOID-LEUKEMIADisease-Free Survival03 medical and health sciencesPROGNOSTIC-FACTORS0302 clinical medicineLeukemia Promyelocytic AcuteOlder patientsRecurrenceRisk FactorsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAnthracyclinesCumulative incidenceELDERLY-PATIENTSAgedCONSOLIDATIONChemotherapyMONOCHEMOTHERAPYbusiness.industryRemission InductionConsolidation ChemotherapyHematologyMiddle Agedmedicine.diseaseCOMPETING RISKSARSENIC TRIOXIDESurgeryRISK-ADAPTED TREATMENTRegimenLeukemiaTreatment OutcomeTRANS-RETINOIC ACIDOncology030220 oncology & carcinogenesisPETHEMA GROUPFemalebusiness030215 immunologyLeukemia
researchProduct

[Macrolides in the treatment of children with Mediterranean spotted fever].

2002

Till now there is not a gold standard therapy for Mediterranean spotted fever (MSF) in children. Standard treatment for MSF is the administration of tetracycline or chloramphenicol, however both these drugs can cause significant adverse effects in children (tetracyclines can cause staining of teeth, chloramphenicol severe hematological adverse events such as aplastic anemia, gray baby syndrome and hemolytic anemia in patients with the Mediterranean form of G6PD deficiency). We conducted two randomized clinical trials; the first compared clarithromycin versus chloramphenicol: mean time to defervescence was 36.7 +/- 18.1 h in the clarithromycin group and 47.1+/- 21.9 h in the chloramphenicol …

MaleAdolescentInfantAzithromycinBoutonneuse FeverAnti-Bacterial AgentsChloramphenicolTreatment OutcomeItalyTetracyclinesChild PreschoolClarithromycinHumansFemaleMacrolidesChildSicilyMediterranean spotted fever macrolidesRandomized Controlled Trials as TopicLe infezioni in medicina
researchProduct

Monkeypox proctitis treated with doxycycline in an HIV MSM returning to Italy from France

2022

No abstract available

MaleAnal painProctitiPublic Health Environmental and Occupational HealthHIV InfectionsMonkeypoxLymphogranuloma venereumAnti-Bacterial AgentsInfectious DiseasesDoxycyclineMonkeypox viruAnti-Bacterial AgentLymphogranuloma Venereum.HumansProctitisHIV InfectionHomosexuality MaleHuman
researchProduct

Erratum to: Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective

2013

Purpose Treatment with cetuximab is accompanied by the development of an acneiform follicular skin exanthema in more than 80 % of patients. Severe exanthema (grade III/IV) develops in about 9–19 % of patients with the necessity of cetuximab dose reduction or cessation. Methods The study presented was a retrospective analysis of 50 gastrointestinal cancer patients treated with cetuximab in combination with either FOLFIRI or FOLFOX. One cohort of 15 patients received an in-house reactive skin protocol upon development of an exanthema. A second cohort of 15 patients received a skin prophylaxis starting with the first dose of cetuximab before clinical signs of toxicity. A third historic group o…

MaleCancer ResearchColorectal cancerAdministration TopicalAdministration OralCetuximabMinocyclineGastroenterologyPeritoneal NeoplasmPeritoneal NeoplasmsGastrointestinal NeoplasmsSkinHematologyintegumentary systemCetuximabTherapy reactiveMultimodal therapyVitamin K 1General MedicineMiddle AgedCombined Modality TherapyAnti-Bacterial AgentsSurvival RateTreatment OutcomeAppendiceal NeoplasmsOncologyColonic NeoplasmsAdenocarcinomaFemaleErratumQuinolizinesFluoroquinolonesmedicine.drugmedicine.medical_specialtyPrednisoloneEGFRDetergentsAntineoplastic AgentsAdenocarcinomaAntibodies Monoclonal HumanizedDisease-Free SurvivalMetronidazoleRashInternal medicineIntestinal NeoplasmsmedicineCombined Modality TherapyHumansSurvival rateAgedRetrospective StudiesOriginal PaperRectal Neoplasmsbusiness.industryRetrospective cohort studyAntibiotic ProphylaxisExanthemamedicine.diseaseDermatologydigestive system diseasesSurgerybusinessJournal of Cancer Research and Clinical Oncology
researchProduct

Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model

2008

Trastuzumab (Herceptin) has improved therapy of breast cancer. Only patients overexpressing ERBB2 are treated with trastuzumab, whereas its use in tumours without ERBB2 expression is useless. This led to the concept that the subgroup of trastuzumab-sensitive tumours is ‘ERBB2-dependent', meaning that ERBB2 signalling is indispensable for growth of these tumours. We used a mouse model that allows anhydrotetracycline (ATc)-controlled downregulation of ERBB2 in tumour tissue. ERBB2 mRNA and protein expression were downregulated below detection limit leading to a macroscopically complete tumour remission within 14 days. Tumour remission was accompanied by a strong decrease in proliferation, a m…

MaleCancer ResearchReceptor ErbB-2AKT1AKT2ApoptosisMiceTrastuzumabPKBskin and connective tissue diseasesERBB2Mitogen-Activated Protein Kinase 3biologyERK1/2herceptinAntibodies MonoclonalCytochromes cImmunohistochemistrynude miceGene Expression Regulation NeoplasticOncologyTetracyclinesKi-67Ki-67Femalemedicine.drugmedicine.medical_specialtyBlotting WesternDown-RegulationMice NudeAntineoplastic AgentsProtein Serine-Threonine KinasesAntibodies Monoclonal Humanizedresistance3-Phosphoinositide-Dependent Protein Kinasesbreast cancerDownregulation and upregulationresponse to therapyInternal medicineHER2medicineAnimalsRNA Messengercytochrome c releaseProtein kinase Bneoplasmstumour developmentCell Proliferationhumanised monoclonal antibodyAktCancerMammary Neoplasms ExperimentalTrastuzumabmedicine.diseaseEndocrinologyKi-67 AntigenApoptosisDrug Resistance Neoplasmbiology.proteinCancer researchreceptor tyrosine kinaseTranslational TherapeuticsProto-Oncogene Proteins c-aktBritish Journal of Cancer
researchProduct